Avecia will incorporate Barofold’s PreEMT™ protein processing platform.

Avecia Biologics will provide BaroFold with process development and cGMP manufacture of its lead compound, BaroFeron™, interferon beta-1b. Interferon betas are used in the treatment of multiple sclerosis and other autoimmune disorders.

Avecia will carry out development work to optimize and scale up the drug manufacturing process for BaroFeron, using BaroFold’s PreEMT™ protein-processing technology. Avecia will integrate the operation of this platform alongside other stages of protein purification in both pilot and cGMP facilities.

PreEMT involves the use of high hydrostatic pressure to potentially disaggregate and refold proteins. It is intended to enable improved, safer, protein therapeutics, potentially providing enhanced product life cycle.

Previous articleC-reactive Protein Linked to Risk of Developing AMD
Next articleGene Involved in Normal Cell Division Discovered